Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…
Read more
  • 0

Mustang Bio launches clinical study combining CAR T cells and oncolytic virus to treat glioblastoma

The cell and gene therapy company Mustang Bio (Nasdaq:MBIO) will initiate a Phase 1 clinical trial combining CAR T cells and oncolytic virus as a potential therapy for recurrent glioblastoma.

The prognosis for glioblastoma is generally poor with approximately 40% survival in the first year following diagnosis, according to the American Association of Neurological Surgeons.

The Worcester, Massachusetts–based company made the announcement after reviewing interim data from two ongoing investigator-sponsored Phase 1 clinical studies testing MB-108 (C134 oncolytic virus) and MB‐101 (City of Hope’s IL13Rα2‐targeted CAR T cell therapy).

Mustang Bio recently shared data supporting the safety of administering MB-108 and MB-101 sequentially in a regimen designated as MB-109 at the American Association for Cancer Research (AACR) Annual Meeting 2022.

“The data presented at the AACR Annual Meeting support the initiation of a Phase 1 clinical trial to evaluate …

Read more
  • 0